Dr. Jonasch on the Promise of Belzutifan in Metastatic RCC

Video

In Partnership With:

Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of the hypoxia inducible factor-2 alpha (HIF-2α) inhibitor belzutifan (Welireg) in metastatic renal cell carcinoma (RCC).

Data from the phase 1 LITESPARK-001 trial (NCT02974738) showed that the HIF-2α inhibitor belzutifan (Welireg) demonstrated an objective response rate (ORR) of 25% and a median progression-free survival (PFS) of 14.5 months in patients with metastatic RCC, Jonasch explains.

Additional studies investigating belzutifan in combination with cabozantinib (Cabometyx) in the frontline and second-line settings have also displayed benefits for patients with metastatic RCC, Jonasch continues. In cohort 1 of the phase 2 LITESPARK-003 trial (NCT03634540), patients with treatment-naïve metastatic RCC who received belzutifan plus cabozantinib experienced an ORR of 57% and a median PFS of 30.3 months, Jonasch concludes.

Related Videos
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD